MX2018004366A - Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos. - Google Patents

Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos.

Info

Publication number
MX2018004366A
MX2018004366A MX2018004366A MX2018004366A MX2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A MX 2018004366 A MX2018004366 A MX 2018004366A
Authority
MX
Mexico
Prior art keywords
cells
epic
sorting
early post
polypeptide
Prior art date
Application number
MX2018004366A
Other languages
English (en)
Inventor
Demaria Christine
R Cairns Victor
Vitko Jason
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2018004366A publication Critical patent/MX2018004366A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente memoria se proporcionan métodos para seleccionar una población de células que expresan un polipéptido blanco. En algunos aspectos, la descripción proporciona métodos para clasificar y seleccionar poblaciones de células hospedantes transfectadas con base a su expresión temprana de un polipéptido seleccionable. En determinadas modalidades, la clasificación se lleva a cabo usando clasificación celular activada por fluorescencia o clasificación celular activada magnéticamente basada en el polipéptido seleccionable. Dichos métodos de selección pueden utilizarse adicionalmente para generar poblaciones clonales de células productoras, p.ej., para fabricación a gran escala de un polipéptido blanco de interés.
MX2018004366A 2015-10-09 2016-10-07 Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos. MX2018004366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239515P 2015-10-09 2015-10-09
PCT/US2016/055918 WO2017062724A1 (en) 2015-10-09 2016-10-07 Early post-transfection isolation of cells (epic) for biologics production

Publications (1)

Publication Number Publication Date
MX2018004366A true MX2018004366A (es) 2018-08-01

Family

ID=57211576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004366A MX2018004366A (es) 2015-10-09 2016-10-07 Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos.

Country Status (10)

Country Link
US (4) US10317329B2 (es)
EP (2) EP3359666A1 (es)
CN (3) CN116660127A (es)
AU (2) AU2016335699A1 (es)
CA (2) CA3001238C (es)
HK (1) HK1259493A1 (es)
IL (4) IL258537B2 (es)
MX (1) MX2018004366A (es)
SG (3) SG11201802829YA (es)
WO (2) WO2017062724A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
RU2749882C2 (ru) 2014-11-14 2021-06-18 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
CA3001238C (en) 2015-10-09 2024-06-25 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7220080B2 (ja) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド ハンチントン病治療組成物及び方法
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
CL2016001661A1 (es) 2016-06-29 2017-03-03 Univ Chile Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM
EP3523440A1 (en) 2016-10-07 2019-08-14 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
EP4124658A3 (en) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
KR20230109683A (ko) 2020-11-19 2023-07-20 젠자임 코포레이션 유세포 분석 감쇠 리포터 발현(플레어) 다중 리포터 시스템 및 이의 사용 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
CA2063799A1 (en) 1989-07-24 1991-01-25 Frank S. Genbauffe Prevention of internal initiation
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
EP1012268A4 (en) 1997-02-25 2001-11-28 Qbi Entpr Ltd IRES SEQUENCES WITH HIGH TRANSLATION EFFICIENCY AND EXPRESSION VECTORS CONTAINING THEM
US7001733B1 (en) * 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US20050005310A1 (en) * 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
EP1196566B1 (en) 1999-07-12 2006-02-01 Genentech, Inc. Expression vectors and methods
AU2001236624A1 (en) 2000-02-02 2001-08-14 Iconix Pharmaceuticals, Inc. Rapid, parallel identification of cell lines
US6833254B2 (en) 2001-03-01 2004-12-21 The Regents Of The University Of California Method to identify IRES elements
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
DE10143238A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente
WO2003099996A2 (en) 2002-05-22 2003-12-04 Biogen Idec Ma Inc. Detection of secreted polypeptides
US7119187B2 (en) 2002-07-09 2006-10-10 National Health Research Institutes Internal ribosome entry site of the labial gene for protein expression
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AU2003252111A1 (en) * 2002-07-19 2004-02-09 Diversa Corporation Fluorescent proteins, nucleic acids encoding them and methods for making and using them
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
US20060173168A1 (en) 2002-12-16 2006-08-03 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
CN101942442B (zh) 2003-06-24 2013-10-09 建新公司 新的β-肌动蛋白和RPS21启动子及其应用
US7776584B2 (en) 2003-08-01 2010-08-17 Genetix Limited Animal cell colony picking apparatus and method
WO2005094886A1 (ja) 2004-03-31 2005-10-13 Kirin Beer Kabushiki Kaisha Gpiアンカー蛋白質アゴニストによる調節性t細胞分化誘導・増殖方法およびそのための医薬組成物
US7078179B2 (en) 2004-05-04 2006-07-18 Newlink Genetics Corporation Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase
US20060188964A1 (en) * 2004-07-28 2006-08-24 Filippo Mancia Processing for producing and crystallizing G-protein coupled receptors
SI1809750T1 (sl) 2004-11-08 2012-08-31 Chromagenics Bv Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina
JP5291341B2 (ja) 2004-11-08 2013-09-18 クロマジェニックス ベー ヴェー タンパク質を高レベルで発現する宿主細胞の選定
CA2588936A1 (en) * 2004-12-14 2006-06-22 F. Hoffmann-La Roche Ag Method for improved selection of rnai transfectants
EP2010668A4 (en) 2006-04-10 2009-04-29 Univ California SYSTEMS AND METHODS FOR EFFICIENT COLLECTION OF UNIQUE CELLS AND COLONIES OF CELLS AND RAPID FORMATION OF STABLE TRANSFECTORS
PL2064337T3 (pl) * 2006-09-20 2012-12-31 Genzyme Corp Oparty na FACS i białku reporterowym układ do wysokowydajnego opracowywania białek terapeutycznych
JP2010521657A (ja) * 2007-03-05 2010-06-24 ニューサウス イノベイションズ ピーティーワイ リミテッド 有糸分裂阻害剤に対する腫瘍細胞の感受性を検出してモジュレートするための方法
US9534246B2 (en) * 2010-07-01 2017-01-03 Glaxo Group Limited Method for selecting high producing cell lines
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US20160017319A1 (en) 2013-03-11 2016-01-21 Audrey Nommay Method of screening cell clones
CA3001238C (en) 2015-10-09 2024-06-25 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production
EP3523440A1 (en) 2016-10-07 2019-08-14 Genzyme Corporation Early post-transfection isolation of cells (epic) for biologics production

Also Published As

Publication number Publication date
IL258538A (en) 2018-05-31
CA3001238C (en) 2024-06-25
EP3359666A1 (en) 2018-08-15
CA3001238A1 (en) 2017-04-13
US20200018682A1 (en) 2020-01-16
EP3359665A2 (en) 2018-08-15
IL258537A (en) 2018-05-31
SG11201802823VA (en) 2018-05-30
IL297805A (en) 2022-12-01
SG11201802829YA (en) 2018-05-30
CN116660127A (zh) 2023-08-29
IL309289A (en) 2024-02-01
US11635363B2 (en) 2023-04-25
SG10202111233SA (en) 2021-11-29
WO2017062724A1 (en) 2017-04-13
IL258537B2 (en) 2024-05-01
IL258538B (en) 2022-12-01
CN108368505B (zh) 2023-02-21
WO2017062722A3 (en) 2017-05-26
HK1259493A1 (zh) 2019-11-29
IL258538B2 (en) 2023-04-01
IL258537B1 (en) 2024-01-01
CN108368505A (zh) 2018-08-03
AU2016335699A1 (en) 2018-05-24
US20170227441A1 (en) 2017-08-10
US20170121734A1 (en) 2017-05-04
US10317329B2 (en) 2019-06-11
CA3001364A1 (en) 2017-04-13
CN108368504A (zh) 2018-08-03
AU2022275507A1 (en) 2023-02-02
US20230304913A1 (en) 2023-09-28
CN108368504B (zh) 2022-07-19
WO2017062722A2 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
MX2018004366A (es) Aislamiento temprano post-transfeccion de celulas (epic) para la produccion de productos biologicos.
CL2017000528A1 (es) Descubrimiento y producción de proteínas biológicas condicionalmente activas en las mismas células hospederas eucariotas de producción
MY189778A (en) Method for producing retinal pigment epithelial cells
NZ762626A (en) Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
SG10201806890VA (en) Massively parallel single cell analysis
GB2527254A (en) Benzylisoquinoline alkaloids (BIA) Producing microbes, and methods of making and using the same
EP3722438A3 (en) Method for production of moth pheromones in yeast
EA201590488A1 (ru) Способы модификации клеток-хозяев
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
MX2016004564A (es) Cultivo celular metabolicamente optimizado.
MX371025B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
MY178364A (en) Method for culturing microalgae of the genus aurantiochytrium in a culture medium without chloride and without sodium for the production of dha
AU2016250905A8 (en) Generation of muscle-lineage cells from stem cells
MY190347A (en) Production method for insoluble recombinant protein aggregate
MX363690B (es) Expansión de celulas madre adultas in vitro.
MY180352A (en) Recombinant methanotrophic bacterium and a method of production of succinic acid from methane or biogas thereof
MX2016000634A (es) Metodo optimizado para la ruptura de paredes celulares de chlorella por medio de homogeneizacion a muy alta presion.
MX2016008258A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
MX2017011220A (es) Metodos para hacer celulas madre neurales y usos de las mismas.
MX2016001396A (es) Seleccion novedosa de vectores y metodos de seleccion de celulas hospederas eucarioticas.
MX2021001528A (es) Metodo para la produccion de celulas positivas para cd3.
WO2016005985A3 (en) Method for reprogramming cells
MX2019004013A (es) Aislamiento temprano de celulas despues de la transfeccion (epic) para la produccion de productos biologicos.
WO2019121961A3 (en) Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin